The United Kingdom and the United States have reached a key commercial pact that will keep zero import taxes on British medicine shipments entering the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on drugs through the public health system. This commitment ensures that tariffs on these key exports will stay at zero for a duration of the next three years.
This agreement comes after recent statements to hike import taxes on patented drug products, with potential rates floated reaching double the cost.
"This agreement between the Britain reinforces the international landscape for new treatments and establishes much-needed balance to U.S.–U.K. medicine commerce," a statement noted.
Economic Importance
Drugs represent one of the the United Kingdom's biggest exports to the United States, which is by far the biggest destination for major UK drugmakers.
Export figures reveal that in the year leading up to September, the UK exported pharmaceutical products valued at billions to the US. This figure represented nearly one-fifth of British export trade in that period.
"This agreement secures jobs, stimulates funding and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official commented.
Specific UK Commitments
The deal entails several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it considers new treatments to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to double overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage manufacturers must refund to the NHS to stay within budget will be limited at 15%. Last year, refunds exceeded 20%.
Recent Tensions
This agreement takes place against a protracted tension between the sector and the ministers over medicine costs and regulatory access.
This friction were intensified by arguments that US customers were charged a premium for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or abandoned, while major investments have been pledged toward US facilities.
A senior figure publicly accepted that the NHS must spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its total funding over the last ten years.
